ReviewCancers2021
Natural History and Treatment Strategies of Advanced PEComas: A Systematic Review.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 33 citations in OpenAlex.
- TFE3-rearranged PEComa with hepatic and pulmonary involvement: diagnostic challenges and resistance to mTOR-targeted therapy.Journal of cancer research and clinical oncology · 2026Article
- MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.Nature communications · 2026Article
- PEComas: current concepts in diagnosis, molecular pathways, and emerging treatments.The oncologist · 2026Review
- Duodenal perforation after retroperitoneal laparoscopic radical nephrectomy for ruptured malignant renal PEComa with spontaneous retroperitoneal hemorrhage: a case report.Frontiers in oncology · 2026Article
- 2 Cases of Large Cystic-Solid Perivascular Epithelioid Cell Tumor: Case Report and Literature Review.Hepatic medicine : evidence and research · 2026Article
- Clinicopathological and molecular features of gynecologic perivascular epithelioid cell tumors: a single-center study.Frontiers in oncology · 2026Article
- Femoral PEComa Treated With Combined Surgery and Radiotherapy: A Case Report.Clinical case reports · 2026Article
- Perivascular Epithelioid Cell Neoplasm of the Lung: A Patient Case Report.Case reports in pathology · 2026Article
- Primary Pulmonary Perivascular Epithelioid Cell Tumour (PEComa): A Case Report.Respirology case reports · 2025Article
- Cracking the code: the emerging role of immune checkpoint inhibitors in PEComas.Immunotherapy · 2025Article
- Review
- Case Report: Malignant perivascular epithelioid cell tumor with aggressive mediastinal invasion and pulmonary metastasis.Frontiers in oncology · 2025Article
- PEComa progressed by mTOR inhibitor therapy with anti-VEGFR TKI combined with PD-1 inhibitor: a case report.Frontiers in oncology · 2025Article
- Case Report: Malignant PEComa of the thyroid combined with follicular carcinoma: a rare case of collision tumor.Frontiers in oncology · 2025Article
- Novel Therapeutics in Soft Tissue Sarcoma.Cancers · 2024Review
- Adrenal PEComa Treated by Surgical Resection and Postoperative Radiotherapy: A Case Report.The American journal of case reports · 2024Article
- Challenges in Diagnosing Metastatic Uterine PEComa: Insights from Two Case Studies.The American journal of case reports · 2024Article
- Hepatic perivascular epithelioid cell tumors: Benign, malignant, and uncertain malignant potential.World journal of gastroenterology · 2024Article
- Perivascular Epithelioid Cell Tumor with Uncertain Malignant Potential Arising in the Round Ligament.Diagnostics (Basel, Switzerland) · 2024Article
- Case report: Liver PEComa after kidney transplantation in recipient with tuberous sclerosis complex.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PEComas is a family of rare mesenchymal tumors. This systematic review aims to better understand the natural history of advanced PEComas. After a search on the PubMed database and main oncology meeting libraries according to the PRISMA guidelines, 88 articles reported in the English literature were included. Data on clinical and histological features, treatments and outcomes were collected. To identify risk factors, univariate and multivariate analyses were performed. Seven cohorts of patients and 124 individual patients were identified. Focusing on case reports, most patients were metastatic, and the median overall survival (OS) of the entire cohort was 60 months (95%CI 33; NA). Risk factors significantly associated with OS in the multivariate analysis were the presence of metastasis at diagnosis (HR: 2.59, 95%CI 1.06; 6.33,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.